Skip to main content

Cost at Issue for New Cholesterol Fighting Drugs

Two drugs that were approved by the FDA last summer have been rejected in large numbers by Express Scripts, the largest pharmacy benefits manager in the U.S., which says many patients do not qualify for the drugs.

Lead image for this article

Two drugs that were approved by the FDA last summer have been rejected in large numbers by Express Scripts, the largest pharmacy benefits manager in the U.S., which says many patients do not qualify for the drugs. The drugs belong to a new class of medicines called PCSK9 inhibitors that can dramatically reduce LDL cholesterol and are aimed at patients with hereditary forms of high cholesterol or those with cardiovascular disease. (Reuters)

Quality journalism doesn't come free

Yes, I'll donate today